Merck’s RSV drug meets key end-stage trial targets

Merck said Tuesday that its respiratory syncytial virus (RSV) drug met safety and efficacy targets in a mid- to late-stage study testing it in infants.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM